HRP20171872T1 - Pripravci koji sadrže benzodiazepine kratkog djelovanja - Google Patents

Pripravci koji sadrže benzodiazepine kratkog djelovanja Download PDF

Info

Publication number
HRP20171872T1
HRP20171872T1 HRP20171872TT HRP20171872T HRP20171872T1 HR P20171872 T1 HRP20171872 T1 HR P20171872T1 HR P20171872T T HRP20171872T T HR P20171872TT HR P20171872 T HRP20171872 T HR P20171872T HR P20171872 T1 HRP20171872 T1 HR P20171872T1
Authority
HR
Croatia
Prior art keywords
preparation
dextran
hygroscopic
pharmaceutically acceptable
mixture
Prior art date
Application number
HRP20171872TT
Other languages
English (en)
Croatian (hr)
Inventor
John Aitken Graham
Alan James Baillie
Kevin Richard WARD
Thomas Peacock
Original Assignee
Paion Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48669863&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20171872(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Paion Uk Limited filed Critical Paion Uk Limited
Publication of HRP20171872T1 publication Critical patent/HRP20171872T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/161,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/161,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/181,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HRP20171872TT 2012-05-22 2013-05-22 Pripravci koji sadrže benzodiazepine kratkog djelovanja HRP20171872T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12168968 2012-05-22
PCT/EP2013/060543 WO2013174883A1 (en) 2012-05-22 2013-05-22 Compositions comprising short-acting benzodiazepines
EP13730128.9A EP2852389B1 (en) 2012-05-22 2013-05-22 Compositions comprising short-acting benzodiazepines

Publications (1)

Publication Number Publication Date
HRP20171872T1 true HRP20171872T1 (hr) 2018-02-23

Family

ID=48669863

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20171872TT HRP20171872T1 (hr) 2012-05-22 2013-05-22 Pripravci koji sadrže benzodiazepine kratkog djelovanja

Country Status (41)

Country Link
US (2) US20150148338A1 (https=)
EP (1) EP2852389B1 (https=)
JP (1) JP6313286B2 (https=)
KR (1) KR102116737B1 (https=)
CN (2) CN108578413A (https=)
AP (1) AP2014008084A0 (https=)
AR (1) AR092008A1 (https=)
AU (1) AU2013265295B2 (https=)
BR (1) BR112014029108B1 (https=)
CA (1) CA2874247C (https=)
CL (1) CL2014003171A1 (https=)
CO (1) CO7151503A2 (https=)
DK (1) DK2852389T3 (https=)
EA (1) EA032119B1 (https=)
EC (1) ECSP14032553A (https=)
ES (1) ES2651389T3 (https=)
FR (1) FR21C1043I2 (https=)
GE (2) GEAP201813666A (https=)
HR (1) HRP20171872T1 (https=)
HU (2) HUE037734T2 (https=)
IL (1) IL235789B (https=)
LT (2) LT2852389T (https=)
LU (1) LUC00230I2 (https=)
MA (1) MA37581B1 (https=)
MX (1) MX368854B (https=)
MY (1) MY185117A (https=)
NL (1) NL301130I2 (https=)
NO (2) NO2852389T3 (https=)
NZ (1) NZ702063A (https=)
PE (1) PE20150683A1 (https=)
PH (1) PH12014502608B1 (https=)
PL (1) PL2852389T4 (https=)
PT (1) PT2852389T (https=)
RS (1) RS56660B1 (https=)
SG (1) SG11201407710VA (https=)
SI (1) SI2852389T1 (https=)
TN (1) TN2014000479A1 (https=)
TW (1) TWI590826B (https=)
UA (1) UA115063C2 (https=)
WO (1) WO2013174883A1 (https=)
ZA (1) ZA201408412B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2657347C (en) 2006-07-10 2014-11-18 Paion Uk Limited Short-acting benzodiazepine salts and their polymorphic forms
EP2305647A1 (en) 2009-09-18 2011-04-06 PAION UK Limited Process for preparing 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4 H-imidazo[1,2-a][1,4]benzodiazepine-4-yl] propionic acid methyl ester or the benzene sulfonate salt thereof, and compounds useful in that process
EP2450039A1 (en) 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
WO2015076340A1 (ja) * 2013-11-21 2015-05-28 小野薬品工業株式会社 全身麻酔および/または鎮静のための注射用組成物
ES2958606T3 (es) 2014-02-10 2024-02-12 Biolumic Ltd Mejoras en y relacionadas con el control de características de organismos fotosintéticos
JP6697806B2 (ja) 2014-03-14 2020-05-27 バイオルミック リミテッド 作物の収量及び/又は品質を改善する方法
HUE047450T2 (hu) 2014-07-23 2020-04-28 Jiangsu Nhwaluokang Pharmaceutical Res And Development Co Ltd Új benzodiazepin származék és alkalmazása
EP4091440A1 (en) 2014-09-17 2022-11-23 Biolumic Limited Method of seed treatments and resulting products
CN105726495B (zh) * 2014-12-12 2019-03-29 宜昌人福药业有限责任公司 一种注射用短效苯并二氮杂卓盐药物组合物及其制备方法
CN107198691A (zh) * 2016-03-17 2017-09-26 江苏恒瑞医药股份有限公司 一种瑞马唑仑的药物组合物
EP3442539B1 (en) * 2016-04-14 2025-04-09 Paion UK Limited Orally inhaled and nasal benzodiazepines
CN108289897B (zh) * 2016-05-20 2020-07-28 江苏恒瑞医药股份有限公司 一种瑞马唑仑的药物组合物
CA3034739A1 (en) 2016-08-22 2018-03-01 Biolumic Limited System, device and methods of seed treatment
CN108503644B (zh) 2016-12-09 2019-06-14 成都倍特药业有限公司 一种苯并二氮杂*衍生物的氢溴酸盐及其制备方法和用途
WO2019002946A1 (en) 2017-06-29 2019-01-03 Biolumic Limited METHOD OF ENHANCING YIELD AND / OR CULTURE QUALITY
EP3714884A1 (en) 2019-03-27 2020-09-30 Paion UK Limited Medical uses for benzodiazepines with a particular eeg pattern
CN112209932B (zh) * 2019-07-12 2023-03-24 成都倍特药业股份有限公司 一种化合物氢溴酸盐的新固体形态及其制备方法和用途
ES2803099B2 (es) * 2019-07-22 2021-11-08 Moehs Iberica Sl Procedimiento de obtención de besilato de remimazolam amorfo
CN114478535B (zh) * 2020-10-23 2024-02-09 成都苑东生物制药股份有限公司 一种苯磺酸瑞马唑仑ii晶型的制备方法
CN112462015B (zh) * 2020-11-18 2022-07-12 海南倍特药业有限公司 一种氢溴酸瑞马唑仑细菌内毒素的检测方法
CN114624351B (zh) * 2020-12-14 2024-04-09 宜昌人福药业有限责任公司 苯磺酸瑞马唑仑原料药中(r)-(-)-1-氨基-2-丙醇残留的分析方法
AU2023394304A1 (en) * 2022-12-16 2025-05-22 Lts Lohmann Therapie-Systeme Ag Oromucosal delivery system containing remimazolam
EP4711368A1 (en) * 2023-06-09 2026-03-18 Chengdu Mfs Pharma. Co., Ltd. Azepine compound, and composition and use thereof
WO2025052259A1 (en) 2023-09-05 2025-03-13 Reena Patel Ready to use compositions of remimazolam

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3520877A (en) * 1967-10-02 1970-07-21 Hoffmann La Roche 3-carbonyl amino acetic acid ethyl ester substituted benzodiazepines
CA2143246C (en) 1994-03-16 2000-08-22 Thierry Godel Imidazodiazepines
PT801651E (pt) 1995-01-06 2001-12-28 Hoffmann La Roche Hidroximetil-imidazodiazepinas e seus esteres
AU4382896A (en) 1995-02-02 1996-08-21 F. Hoffmann-La Roche Ag Acetylimidazobenzodiazepines
JPH0971533A (ja) * 1995-06-30 1997-03-18 Takeda Chem Ind Ltd 凍結乾燥製剤
GB9911152D0 (en) * 1999-05-14 1999-07-14 Glaxo Group Ltd Short-acting benzodiazepines
US7160880B1 (en) * 1999-05-14 2007-01-09 Cenes Limited Short-acting benzodiazepines
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
EP1161949A1 (en) * 2000-06-09 2001-12-12 Warner-Lambert Company Use od diazepinoindoles for the treatment of chronic obstructive pulmonary disease
MX2007009915A (es) * 2005-02-15 2007-11-06 Elan Pharma Int Ltd Formulaciones en aerosol e inyectables de benzodiazepina nanoparticulada.
GB0613692D0 (en) * 2006-07-10 2006-08-16 Cenes Ltd Benzodiazepine salts
CA2657347C (en) * 2006-07-10 2014-11-18 Paion Uk Limited Short-acting benzodiazepine salts and their polymorphic forms
GB0613693D0 (en) * 2006-07-10 2006-08-16 Cenes Ltd Benzodiazepine salts (3)
CN101352422B (zh) * 2008-09-17 2011-04-20 厦门朝阳生物工程有限公司 河豚毒素冻干粉针制剂及其制备方法
RS54645B1 (sr) * 2009-11-05 2016-08-31 Glaxosmithkline Llc Benzodiazepin kao inhibitor bromodomena
EP2450039A1 (en) * 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
CN102964349A (zh) * 2011-08-31 2013-03-13 江苏恒瑞医药股份有限公司 苯并二氮杂*衍生物的托西酸盐及其多晶型、它们的制备方法和用途

Also Published As

Publication number Publication date
KR102116737B1 (ko) 2020-05-29
DK2852389T3 (en) 2017-12-18
GEAP201813666A (en) 2018-01-25
JP6313286B2 (ja) 2018-04-18
HUE037734T2 (hu) 2018-09-28
EA032119B1 (ru) 2019-04-30
NO2021041I1 (no) 2021-09-20
US20220040198A1 (en) 2022-02-10
WO2013174883A1 (en) 2013-11-28
LT2852389T (lt) 2017-12-27
RS56660B1 (sr) 2018-03-30
PT2852389T (pt) 2017-12-13
AP2014008084A0 (en) 2014-11-30
CL2014003171A1 (es) 2015-06-19
AR092008A1 (es) 2015-03-18
SG11201407710VA (en) 2015-01-29
SI2852389T1 (en) 2018-02-28
LTC2852389I2 (https=) 2024-11-25
MA37581B1 (fr) 2016-07-29
CN108578413A (zh) 2018-09-28
AU2013265295A1 (en) 2015-01-22
IL235789A0 (en) 2015-01-29
PH12014502608A1 (en) 2015-01-21
TWI590826B (zh) 2017-07-11
JP2015517552A (ja) 2015-06-22
KR20150009601A (ko) 2015-01-26
EP2852389B1 (en) 2017-10-18
US20150148338A1 (en) 2015-05-28
CA2874247C (en) 2020-07-28
NO2852389T3 (https=) 2018-03-17
MX368854B (es) 2019-10-18
FR21C1043I2 (fr) 2022-10-07
LTPA2021521I1 (https=) 2021-10-11
PH12014502608B1 (en) 2019-11-27
EA201492160A1 (ru) 2015-10-30
IL235789B (en) 2019-07-31
UA115063C2 (uk) 2017-09-11
ZA201408412B (en) 2016-09-28
ECSP14032553A (es) 2018-11-30
PE20150683A1 (es) 2015-06-03
EP2852389A1 (en) 2015-04-01
TW201400119A (zh) 2014-01-01
HUS2100040I1 (hu) 2021-10-28
LUC00230I2 (https=) 2022-10-07
GEP20186852B (en) 2018-05-25
NL301130I2 (nl) 2021-10-25
CO7151503A2 (es) 2014-12-29
MX2014014225A (es) 2015-06-17
PL2852389T3 (pl) 2018-02-28
CA2874247A1 (en) 2013-11-28
CN104968348B (zh) 2018-04-17
HK1208164A1 (en) 2016-02-26
TN2014000479A1 (en) 2016-03-30
FR21C1043I1 (https=) 2021-11-19
MY185117A (en) 2021-04-30
BR112014029108B1 (pt) 2022-02-08
NL301130I1 (https=) 2021-09-22
BR112014029108A2 (pt) 2017-06-27
MA20150233A1 (fr) 2015-07-31
NZ702063A (en) 2016-11-25
AU2013265295B2 (en) 2017-08-31
ES2651389T3 (es) 2018-01-26
PL2852389T4 (pl) 2022-02-21
CN104968348A (zh) 2015-10-07

Similar Documents

Publication Publication Date Title
HRP20171872T1 (hr) Pripravci koji sadrže benzodiazepine kratkog djelovanja
JP2015517552A5 (https=)
HRP20210813T1 (hr) Piridinonpiridinilni spojevi supstituirani s metil/fluorpiridinilmetoksi i piridinonpiridinilni spojevi supstituirani s fluorpirimidinilmetoksi
HRP20180746T4 (hr) Supstituirani spojevi pirazolo[1,5-]pirimidina kao inhibitori trk kinaze
HRP20220885T1 (hr) Spojevi imidazo[4,5-d]pirolo[2,3-b]piridina kao inhibitori janus kinaze
ES2212580T3 (es) Inhibidores de la proteina farnesil-transferasa para el tratamiento de artropatias.
HRP20151250T1 (hr) Derivati izoksazolo-piridina
HRP20201641T1 (hr) Novi spojevi i njihove farmaceutske kompozicije za liječenje inflamatornih poremećaja
AR032335A1 (es) Polimorfos del compuesto triazolo [4,5-d] pirimidina, una mezcla, proceso para su preparacion, composicion farmaceutica, y uso de estos compuestos para la fabricacion de medicamentos
IL256375A (en) New histological histories, process for their preparation and pharmaceutical preparations containing them
HRP20090459T1 (hr) Aminofenil derivati kao novi inhibitori histonskih deacetilaza
HRP20110498T1 (hr) Azetidini kao inhibitori mek za liječenje proliferativnih bolesti
HRP20180528T1 (hr) Derivati naftiridina, korisni kao antagonisti alfa-v-beta-6 integrina
HRP20171150T1 (hr) Novi spojevi
YU53298A (en) Aryl pyrimidine derivatives
AR086546A1 (es) Derivados de 7h-purin-8(9h)-ona como inhibidores de jak
HRP20161657T1 (hr) Kinazolinoni kao inhibitori humane fosfatidilinozitol 3- kinaze delta
HRP20140593T1 (hr) Derivati 1,3-disupstituiranih imidazolidin-2-ona kao cyp 17-inhibitori
HRP20231413T1 (hr) Derivati bicikličnih heteroarila kao inhibitori ektonukleotid pirofosfataze fosfodiesteraze 1
BR112013014184A2 (pt) compostos de triazina [1,2,4] triazolo [4,3-b][1,2,4], método de preparo e seu uso
BR112014006840A2 (pt) derivados de pirrolopirimidina e purina
AR087355A1 (es) Derivados de piridin-2(1h)-ona como inhibidores de jak
AR074171A1 (es) Derivados de pirazolopiridina, composicion farmaceutica que los comprende y su uso en el tratamiento de afecciones mediadas por pkctheta
NZ598907A (en) Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors
EA201001017A1 (ru) 3h-[1,2,3]триазоло[4,5-d]пиримидиновые соединения, их применение в качестве ингибиторов киназы mtor и киназы pi3 и их синтезы